bioMerieux supply/service news
bioMerieux will restructure and reduce headcount by 100. The cuts will come from the closure of its Portland, Ore., facility which is expected 2H11. The company will discontinue the manufacturing of prepared media for clinical applications, representing annual revenue of $9 million, and transfer production of LyfoCults lines of quality control organisms to a microbiology site. In North America, bioMerieux will focus on its chromID chromogenic culture media range to identify bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The company expects the closing of the Portland site, which it gained through its 2008 acquisition of PML Microbiologicals Inc., to save about $3 million annually. ...